Cord Blood Alarin Levels in Term Babies

Birth Weight Clinical Trial

Official title:

Comparison of Cord Blood Alarin Levels in Term Babies According to Birth Weight

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06333548
• Other study ID #: KSH_MB_2024_1
• Status: Completed
• Start date: September 18, 2023
• Est. completion date: January 15, 2024

Study information

• Verified date: March 2024
• Source: Konya City Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In this study, alarin levels in the cord blood of babies with large birth weights will be compared with babies of normal weight. Thus, the investigators aimed to find out whether there is a relationship between babies' birth weights and alarin.

Description:

Studies have shown that the galanin neuropeptide family plays a role in regulating appetite, insulin resistance, obesity, hypertension and metabolism. Alarin is a peptide consisting of 25 amino acids. Current research shows that allerin plays an important role in the emergence and development of diabetes and obesity. There are studies that found that the serum alarin level increased significantly in patients with impaired glucose tolerance and type 2 diabetes mellitus. Additionally, studies have found that both non-obese and obese type 2 diabetes mellitus serum alarin levels increase.

Studies in the literature are related to adults, and there are no studies on alarin levels in newborn babies.

Based on the alarin studies available in the literature, the investigators determined whether there is a relationship between the alarin level and the baby's birth weight by comparing the alarin level in the cord blood of babies with a high birth weight according to their gestational age (both babies of diabetic mothers and babies of non-diabetic mothers) compared to babies whose birth weight is within the normal range. the investigators aimed to find it.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 87
• Est. completion date: January 15, 2024
• Est. primary completion date: December 23, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Minute to 5 Minutes

Eligibility

Inclusion Criteria:

• Babies given consent by their families

• Healthy babies

Exclusion Criteria:

• Babies with syndromic appearance or any accompanying disease

• Babies whose family does not give consent

Related Conditions & MeSH terms

• Birth Weight

Intervention

Diagnostic Test:
• Appropriate for gestational age , small for gestational age, large for gestational age, Baby of mother diagnosed with GDM
No intervention

Locations

Country	Name	City	State
Turkey	MELEK	Konya	Sihhiye

Sponsors (1)

Lead Sponsor	Collaborator
Konya City Hospital

Country where clinical trial is conducted

Turkey, 

References & Publications (2)

Hu W, Fan X, Zhou B, Li L, Tian B, Fang X, Xu X, Liu H, Yang G, Liu Y. Circulating alarin concentrations are high in patients with type 2 diabetes and increased by glucagon-like peptide-1 receptor agonist treatment: An Consort-compliant study. Medicine (B — View Citation

Zhou X, Luo M, Zhou S, Cheng Z, Chen Z, Yu X. Plasma Alarin Level and Its Influencing Factors in Obese Newly Diagnosed Type 2 Diabetes Patients. Diabetes Metab Syndr Obes. 2021 Jan 27;14:379-385. doi: 10.2147/DMSO.S290072. eCollection 2021. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison of cord blood alarin levels of babies in different groups according to birth weight (low-appropriate-large) and babies of mothers diagnosed with gestational diabetes regardless of birth weight.	umbilical cord blood alarin levels	postnatal 5 minutes